Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Micromedic Technologies

Lithocholic Acid Kills Cancer, Spares Healthy Cells

By BiotechDaily International staff writers
Posted on 19 Jan 2012
Print article
Lithocholic acid (LCA), naturally generated in the liver during digestion, has been seriously underestimated because new research has revealed that LCA can kill several kinds of cancer cells, such as those found in breast cancer and various brain tumors.

The researchers, led by Concordia University (Austin, TX, USA), included scientists from McGill University (Montreal, Canada) and the Jewish General Hospital’s Lady Davis Institute (Montreal, Canada), as well as the University of Saskatchewan (Saskatoon, Canada). The study’s findings were published October 2011 in the journal Oncotarget.

Earlier research from the same investigators demonstrated LCA also extends the lifespan of aging yeast. This time, the team found LCA to be very selective in killing cancer cells while leaving normal cells unscathed. This could translate into a great improvement over the indiscriminant all-cell damaging drugs used in chemotherapy.

“LCA doesn’t just kill individual cancer cells. It could also prevent the entire tumor from growing,” stated senior author Vladimir Titorenko, a professor in the department of biology and Concordia University research chair in genomics, cell biology, and aging.

Moreover, LCA prevents tumors from releasing substances that cause neighboring cancer cells to grow and proliferate. Prof. Titorenko noted that LCA is the only compound that targets cancer cells, which could translate into tumor-halting power. “This is important for preventing cancer cells from spreading to other parts of the body,” he said, noting that unlike other antiaging compounds, LCA blocks cancer cell growth yet lets normal cells continue to grow.

The next phase for the research team will be to test LCA’s effect on different cancers in mice models. Prof. Titorenko expects that LCA will also kill cancer cells in the research and lead to human clinical trials. “Our study found that LCA kills not only tumors [neuroblastomas], but also human breast cancer cells,” said Prof. Titorenko. “This shows that it has a wide effect on different types of cancers.”

Prof. Titorenko emphasized that dissimilar to agent utilized in chemotherapy, LCA is a natural compound that is already present in humans. Studies have shown that LCA can be safely given to mice by adding it to their food. Therefore, scientists are looking into why LCA is so lethal for cancer cells. Prof. Titorenko conjectures that cancer cells have more sensors for LCA, which makes them more sensitive to the compound than normal cells.

LCA sensors transmit signals to mitochondria. It seems that when these signals are too strong, mitochondria self-destruct and take the cell along with them. Simply stated, Prof. Titorenko and his colleagues engaged in cancer cell disruption by targeting a weakness to LCA.

Related Links:
Concordia University
McGill University
Jewish General Hospital’s Lady Davis Institute



Print article

Channels

Genomics/Proteomics

view channel
Image: Top: Overview of the structure of T-STAR STAR domain in complex with AUUAAA RNA. Bottom left: close up view of the specific recognition of the RNA. Bottom right: close up view of the KH dimerization interface (Photo courtesy of the University of Leicester).

Atomic Structures of Alternative Splicing Regulator Proteins May Lead to New Anticancer Drugs

A detailed structural analysis of two RNA-binding proteins that regulate alternate splicing of gene expression, which can lead to various types of cancer, is expected to aid in the development of drugs... Read more

Drug Discovery

view channel
Image: Naturally occurring clay from Kisameet Bay, Canada, exhibits potent antibacterial activity against multidrug-resistant pathogens (Photo courtesy of Kisameet Glacial Clay Inc.).

Antibiotic Resistant Bacteria Succumb to Treatment with Unique Natural Clay

A team of Canadian medical microbiologists has demonstrated the potential use of a unique type of natural clay for treating pathogenic bacteria that have become resistant to the commonly used antibiotics.... Read more

Business

view channel

Purchase Agreement to Boost Ebola Vaccine Development

A deal to help boost development of a vaccine to protect against Ebolavirus infection was finalized at the recent Davos Conference in Switzerland. Gavi (Geneva, Switzerland), the global alliance for vaccines and immunizations, announced that it would spend five million USD to purchase the Ebola vaccine under development... Read more
Copyright © 2000-2016 Globetech Media. All rights reserved.